EICHORCondition: Parkinson Disease · Sponsor: Intra-Cellular Therapies, Inc.
This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ITI-214.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Major Inclusion Criteria: * Clinical diagnosis of idiopathic Parkinson's disease (PD) * Severity of PD assessed by Hoehn and Yahr Staging score of 1 to 3 * Maintenance on stable PD therapy Major Exclusion Criteria: * Clinical signs of dementia * Suicidal ideation or behavior * Considered medically inappropriate for study participation
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Atlanta Center for Medical Research | Atlanta, Georgia, United States | — |
| Duke Early Phase Research Unit | Durham, North Carolina, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03257046